It seems that life gets more and more complicated; this is true as well of the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) seventh edition of the lung cancer staging system. The increased granularity brought about by the huge increase in the database and the underlying analysis has made the system less intuitive and difficult, if not impossible, to remember.1,2 Both for those who deal with lung cancer occasionally and for focused subspecialists, this increased level of detail represents a challenge. Being correct about the stage is crucial in applying the right data and selecting the optimal treatment for patients. A simple example of the increasing complexity is in the patient with an additional malignant lesion in a different lobe of the ipsilateral chest who, according to the seventh edition lung cancer staging system, will be considered to have a T4 tumor rather than an M1 tumor, as in the sixth edition of the lung cancer staging system. If this patient had no lymph node involvement or disease limited to the ipsilateral chest, this would mean that the patient has a stage IIIA tumor rather than a stage IIIB tumor based on the seventh edition of the lung cancer staging system.